NEW YORK, Dec. 24, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, a global investor rights firm, has filed a class action lawsuit on behalf of purchasers of Roka Bioscience, Inc. common stock (Nasdaq:ROKA) in its July 17, 2014 initial public offering ("IPO") and on the open market between July 17, 2014 and November 6, 2014. The lawsuit seeks to recover investor losses under the federal securities laws.
To join the Roka class action, go to the website at http://www.rosenlegal.com/cases-466.html or call Phillip Kim, Esq. or Laurence Rosen, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or lrosen@rosenlegal.com for information on the class action. The suit is pending in U.S. District Court for the District of New Jersey.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Roka's initial public offering documents failed to disclose known trends and uncertainties about the drastic decline in demand for its Atlas instruments that existed at the time of the IPO. On November 6, 2014, Roka announced a surprise loss of ($0.64) per share in the third quarter of 2014. Roka admitted that it had not placed any Atlas instruments in that quarter. That day, Roka's stock price fell from $8.34 to $3.00, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 23, 2015. If you wish to join the litigation and recover your investment losses go http://www.rosenlegal.com/cases-466.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Laurence Rosen, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or lrosen@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.